Search Weight Loss Topics:




Sep 1

Ascendis Pharma A/S American (NASDAQ:ASND) Experiences Heavy Trading Volume – Modern Readers

Advertisement

413K shares changed hands by the end of trading on Friday. Volume was up 889.49% over the stocks average daily volume.

Investors are more bullish on the company lately if you take into consideration the downtick in short interest. The stock saw a fall in short interest of -2.21% as of the latest report on August 15, 2017. Short shares decreased from 344,109 to 336,495 over that timeframe. The days to cover increased to 7.0 and the percentage of shorted shares was 0.01% on August 15.

Here are some other firms who have updated their holdings. As of quarter end Venbio Select Advisor LLC had bought a total of 290,000 shares growing its position 41.4%. The value of the companys investment in Ascendis Pharma A/S American increased from $19,626,000 to $27,508,000 a change of $7,882,000 quarter over quarter. As of the end of the quarter Vhcp Management Ii, LLC had acquired 175,000 shares growing its stake by 21.6%. The value of the investment in Ascendis Pharma A/S American went from $22,722,000 to $27,385,000 increasing 20.5% for the reporting period.

Janus Capital Management LLC downsized its holdings by selling 35,260 shares a decrease of 5.9% as of 03/31/2017. Janus Capital Management LLC owns 559,035 shares worth $15,653,000. The value of the position overall is up by 30.1%. As of quarter end Foresite Capital Management Iii, LLC had sold 77,600 shares trimming its holdings by 77.6%. The value of the investment in (ASND) decreased from $2,800,000 to $622,000 a change of 77.8% quarter to quarter.

The company is up from yesterdays close of $27.12.

Ascendis Pharma A/S, launched on September 21, 2006, is a clinical-stage biopharmaceutical company. The Company is involved in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism. The Businesss subsidiaries include Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark) and Ascendis Pharma Growth Disorders A/S (Denmark)..

See the article here:
Ascendis Pharma A/S American (NASDAQ:ASND) Experiences Heavy Trading Volume - Modern Readers

Your Full Name
Your Email
Your Phone Number
Select your age (30+ only)
Select Your US State
Program Choice
Confirm over 30 years old Yes
Confirm that you resident in USA Yes
This is a Serious Inquiry Yes
Message:
captcha


Related Post